Mode
Text Size
Log in / Sign up
Phase 4 Completed N=153 Randomized Quadruple-blind Treatment

Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence

Stress Incontinence
Source: ClinicalTrials.gov NCT00734968 ↗
Enrolled (actual)
153
Serious AEs
0.0%
Results posted
Oct 2016
Primary outcomePrimary: Incidence of Post-operative UTI Following the Placement of Sub-urethral Sling for the Treatment of Stress Urinary Incontinence — 13; 24 participants
◆ Published Evidence
Established
35citations · ~3 / year
Antibiotic prophylaxis for urinary tract infection after midurethral sling: a randomized controlled trial.
Female pelvic medicine & reconstructive surgery · 2013 · Likely link

Summary

This project will determine whether post-operative prophylaxis with macrobid will decrease the incidence of postoperative urinary tract infection in women receiving sub-urethral slings for the treatment of urinary incontinence.

Linked Publications (2)

  • Antibiotic prophylaxis for urinary tract infection after midurethral sling: a randomized controlled trial.
    Female pelvic medicine & reconstructive surgery · 2013 · 35 citations · Likely link
  • Prophylactic antibiotics for preventing infection after continence surgery in women with stress urinary incontinence.
    The Cochrane database of systematic reviews · 2022 · 2 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Incidence of Post-operative UTI Following the Placement of Sub-urethral Sling for the Treatment of Stress Urinary Incontinence
13; 24
PRIMARY
Incidence of Post-operative UTI in Placebo Group
13; 24
PRIMARY
Incidence of Post-operative UTI in Treatment Group
13; 24

Eligibility Criteria

Inclusion Criteria

  • Women over the age of 18 who will undergo the placement of a sub-urethral sling for the treatment of stress urinary incontinence

Exclusion Criteria

  • Exclusion criteria are those with a known allergy to macrobid, those with glucose-6-phosphate deficiency, renal impairment, women breast feeding or with a known pregnancy, patients taking medications for gout, and those with known risk factors for complicated UTI (polycystic renal disease, nephrolithiasis, neurogenic bladder, diabetes, immuno-suppression, etc).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00734968) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search